对布洛芬颗粒溶出度一致性评价的探索

目的建立布洛芬颗粒的溶出度测定法,并通过多条溶出曲线考察其与参比制剂的一致性。方法分别以水、pH=1．2盐酸溶液、pH=5．5磷酸氢二钠-柠檬酸缓冲液、pH=6．8磷酸盐缓冲液及pH=7．2磷酸盐缓冲液各900mL为溶出介质,转速为50r·min^-1,采用高效液相色谱法于263nm测定。结果布洛芬在40．15～280．99μg·mL^-1与峰面积呈良好的线性关系（r=0．9999）;平均回收率为99．4％,RSD为0．40％;在4种溶出介质中,15min累积溶出基本达到平衡,样品与参比制剂溶出行为基本一致。结论该方法准确、可靠,可用于布洛芬颗粒溶出度评价。     

布洛芬软胶囊的溶出度测定

目的建立布洛芬软胶囊溶出度的测定方法,方法以磷酸盐缓冲液（pH 7.2）900 ml为溶出介质,采用转篮法（120 r.min^-1）45 min取样,运用HPLC法对其溶出度进行测定,并考察了溶出曲线。结果样品溶出均一性良好,溶出度均〉90%。布洛芬软胶囊与市售片剂相比,其溶出速率有明显提高。结论本法能考察和控制布洛芬软胶囊的质量。     

布洛芬颗粒溶出度测定方法研究

目的建立布洛芬颗粒溶出度测定方法。方法采用紫外分光光度法测定。测定波长为：220nm。溶出介质为pH7．2磷酸盐缓冲液。结果布洛芬溶液在3．0-15．0μg／ml范围内,吸收度与浓度呈良好的线性关系,r=0．9993。样品精密度试验RSD为0．85％,样品供试液在12h内稳定,样品加样回收率为99．9％,RSD为0．22％。结论该法操作简便,稳定可靠,专属性强,可以有效测定布洛芬颗粒溶出度,为控制布洛芬颗粒质量提供了依据。     

心脑欣滴丸中山柰酚的体外溶出度测定

目的:建立心脑欣滴丸中山柰酚的体外溶出度的测定方法,比较心脑欣滴丸和胶囊中山柰酚的体外溶出行为.方法:选择小杯法作为溶出方法,并考察了转速和溶出介质对山柰酚溶出的影响;采用HPLC法进行山柰酚含量测定,并比较了滴丸剂与胶囊剂中山柰酚的体外溶出度.结果:确定溶出条件中,转速为100 r·min-1,溶出介质为含3 g·L-1吐温80的双蒸水100 mL;胶囊剂和滴丸剂中山柰酚的1h累积溶出率分别为53％和95％.结论:本研究建立的心脑欣滴丸山柰酚的体外溶出度测定方法准确、可靠,可用于心脑欣滴丸的质量控制;滴丸剂可使难溶药物的溶出显著改善.     

法莫替丁滴丸的制备及其溶出度与含量考察

以聚乙二醇4000为基质，设计法莫替丁滴丸剂的处方，考察其溶出速度。结果表明法莫替丁滴丸在10分钟内溶出80％，采用高效液相色谱法对法莫替丁滴丸含量进行测定，表明法莫替丁滴丸剂是一种释放速度快、性质稳定的制剂。     

布洛芬片剂处方组成的优选

采用均匀设计优选出布洛芬片剂最佳处方组成。按该处方组成压制成的片剂Ａ与市售片剂Ｂ、Ｃ进行体外溶出速率试验。结果表明：外溶出度参数间均匀有显著性差异（Ｐ＜０．０５），说明该方片比市售片释放快 。     

复方胶囊中右美沙芬和布落芬的溶出度测定

用ＨＰＬＣ测定复方胶囊中右美沙芬、布洛芬的溶出度。色谱柱为Ｓｈｉｍｐａｃｋ ＣＬＣ－ＯＤＳ柱,流动相为乙脯－水（６５：３５含０．００７ｍｏｌ／Ｌ硝酸铵、０．００７ｍｏｌ／Ｌ ＳＤＳ,用冰醋酸调ＰＨ至３．４）,流速１．０ｍｌ／ｍｉｎ,在２７０ｎｍ处测定。右美沙芬、布洛芬的线性范围分别为５～４０,５０～４００μｇ／ｍｌ。两者的平均回经分别为９９．２６％、９９．７０％。     

阿莫西林胶囊剂与片剂溶出度考察

采用紫外分光光度法对5个厂家生产的阿莫西林胶囊剂与片剂进行体外溶出度考虑。结果表明，国产胶囊剂YN产品怎出最快，30min时已达90．3％；HN及HB的本品在45min时分别溶出84．3％，87．2％；进口胶囊剂HG的本品溶出最慢，45min仅溶出76．1％，而国产片剂SX产品在45min时已达84％。不同厂家胶囊剂的溶出度参数（T50，Td）具有极显著差异（P＜0．01）；片剂SX与胶囊剂溶出度参数YN（T50，Td）及HB（Td）无显著差异（P＜0．05）。因此，我们认为国产阿莫西林胶囊剂质量可靠，完全可替代进口产品，国产片剂工艺较合理，对体外溶出度影响不明显。     

光纤药物溶出仪实时测定布洛芬片溶出度的研究

目的采用光纤药物溶出度实时测定(fiber-optic in situ dissolution testing,FODT)仪监测布洛芬片溶出度。方法取不同厂家和批号的布洛芬片,用FODT仪分别监测其溶出曲线和开始溶出、溶出50%及溶出70%的时间,以及与药典法比较30min时平均累积溶出百分率。结果FODT仪测定布洛芬糖衣片和普通片的溶出曲线不同;3个溶出段的时间各异;与中国药典2005年版二部法相比,尽管各药片溶出度均达合格标准,但30min时平均累积溶出百分率数值有差异。结论FODT法可用于布洛芬片溶出度检查。     

布洛芬颗粒的溶出度测定及评价

目的：创建一种测定布洛芬颗粒溶出度的方法。方法：采用桨法,pH值7.2磷酸盐缓冲液500ml为溶出介质,转速50r/min,采用高效液相法测定含量及溶出曲线,并用f2相似因子法进行比较分析。结果：布洛芬颗粒的进样量在0.04～0.6（mg/ml）（r=0.9999）的范围内线性关系良好,平均回收率99.7%,RSD=0.52%。结论：本法准确、可行性强,可作为布洛芬颗粒的质量标准中控制项目之一。     

不同基质的吴藿降压滴丸中吴茱萸碱体外溶出研究

目的:比较不同基质的吴藿降压滴丸中吴茱萸碱体外溶出差异。方法:分别以泊洛沙姆-188、聚乙二醇(PEG)4000、PEG6000为基质,制备吴藿降压滴丸;测定各滴丸中吴茱萸碱的体外溶出度,绘制溶出曲线,求出累积溶出参数,并进行分析。结果:以泊洛沙姆-188、PEG4000、PEG6000为基质制备的滴丸中吴茱萸碱的溶出度分别为99.1%、95.2%、93.6%。以PEG4000、PEG6000为基质制备的滴丸中吴茱萸碱溶出速度较泊洛沙姆-188快,但吴茱萸碱溶出量较后者低。结论:泊洛沙姆-188、PEG类均为非离子型表面活性剂,对吴茱萸碱的溶出起增溶作用,泊洛沙姆-188增溶效果强于PEG类。     

通心舒滴丸成型工艺研究

目的　通过试验选择通心舒滴丸最佳的成型工艺。方法　以滴丸的溶散时间、丸重差异变异系数及外观质量作为综合评定指标,对药物清膏与基质的比例、基质配比(PEG4 0 0 0与PEG6 0 0 0的比例)、滴速、药液温度以正交试验法实验,优选出滴丸最佳成型工艺。结果　以清膏∶基质 =1∶2 5,PEG4 0 0 0∶PFG6 0 0 0 =1∶1,滴速为 4 5滴·min-1,药液温度为 85℃进行滴制,为最佳成型工艺。结论　本试验筛选出滴丸的最佳成型工艺,滴丸外观性状好、溶散度较好,丸重差异小,符合滴丸剂的质量标准。     

Influence of rapeseed phospholipids on ibuprofen dissolution from solid dispersions

The dissolution profiles of ibuprofen (IB) from solid dispersions prepared by the solvent evaporation method, containing the rapeseed lecithin ethanol soluble fraction (LESF) or rapeseed phosphatidylcholine (RPC) have been determined. The effect of incorporation of PEG 4,000 or PEG 8,000 in the solid dispersions on the controlled-release of IB was also investigated. Dissolution studies conducted in double-distilled water using the paddle dissolution apparatus showed that the initial dissolution rate (IDR) within the first 5 min and the maximum percent of dissolved IB of IB/LESF were double of those of IB/RPC (both in ratio 4:1 w/w). The low amounts of LESF markedly increased dissolution of IB. Increasing of LESF concentration from 0 to 10 and 20% in solid dispersions produced 60 and 100% improvement of IB maximum dissolution level respectively, to compare with that of IB alone. PEG 4,000 caused the slightly decreasing in IB dissolution rate, while PEG 8,000 markedly improved the dissolution of IB in examined conditions.     

黄芩苷滴丸的制备工艺优选

目的优化黄芩苷滴丸制备工艺,考察药物体外释放度。方法以聚乙二醇6000（PEG6000）．共聚雏酮（PVPS630）为基质制备黄芩苷滴丸,以圆整度和重量差异为评价指标,通过正交试验优化制备工艺。结果,最佳处方和制备工艺条件为：黄芩苷、PEG6000、PVPS630质量比为1：9：1,滴制时药料温度80～90℃,滴距6cm,滴速30滴／min,二甲基硅油为冷却剂,冷却温度为10～15℃。制备的滴丸在40min的平均溶出度为86．54％。结论优选的黄芩苷滴丸制备工艺合理可行。能增加药物的溶出度。     

Pharmacokinetics of ibuprofen sodium dihydrate and gastrointestinal tolerability of short-term treatment with a novel, rapidly absorbed formulation

OBJECTIVE: This paper describes four studies investigating the dissolution, plasma pharmacokinetics and safety of a novel, fast-acting ibuprofen formulation, ibuprofen sodium dihydrate. MATERIAL AND METHOD: Four separate studies investigated: the in vitro dissolution rates of ibuprofen sodium dihydrate (at pH 1.2, 3.5 and 7.2); the bioavailability of ibuprofen sodium dihydrate (in two pharmacokinetic studies; combined n = 38) compared with conventional ibuprofen, ibuprofen lysinate, ibuprofen arginate and ibuprofen liquagels (all 2 x 200 mg ibuprofen); and the gastroduodenal tolerance of ibuprofen sodium dihydrate and ibuprofen arginate (both 2 x 200 mg ibuprofen t.i.d.) in an endoscopy safety study, where endoscopy was performed at baseline and at the end of each treatment period using a five-point scale to assess the integrity of the gastric and duodenal mucosa. RESULTS: Ibuprofen sodium dihydrate dissolved significantly more rapidly at pH 1.2, 3.5 and 7.2 than conventional ibuprofen, ibuprofen lysinate and ibuprofen liquagels. Ibuprofen sodium dihydrate had similar C(max) to ibuprofen lysinate and ibuprofen liquagels and significantly higher Cmax than conventional ibuprofen (p = 0.002). The mean plasma concentration for ibuprofen sodium dihydrate was significantly higher than for conventional ibuprofen (p = 0.028) 10 minutes post-dose and the t(max) for ibuprofen sodium dihydrate was reached significantly earlier than for conventional ibuprofen (p = 0.018). All three formulations were bioequivalent according to the acceptable boundaries (90% confidence intervals). No statistically significant difference was observed between the ibuprofen formulations in terms of adverse events and specifically with respect to hemorrhagic scores; 41 (46.0%) adverse events (AEs) occurred after administration of ibuprofen sodium dihydrate, and 46 (52.9%) after ibuprofen arginate. One occurrence of an invasive ulcer was observed after administration of ibuprofen arginate. CONCLUSIONS: The new formulation of ibuprofen sodium dihydrate dissolves quickly in vitro, has the same extent of absorption as other fast-acting ibuprofen formulations, and is absorbed into plasma more rapidly than conventional ibuprofen. In addition, the present studies suggest that the tolerability and safety profile of ibuprofen sodium dihydrate is comparable to existing ibuprofen formulations.     

以聚醚为基质研制耳用滴丸

采用水溶性非离子型表面活性剂聚醚作基质制备吡哌酸耳用滴丸。与 PEG 制备的滴丸比较,两种滴丸的溶出度和透皮吸收率有显著差异。聚醚所制滴丸溶出及吸收均较慢,但制备工艺简单,兔口服给药的药动学参数两种滴丸未见差异。     

联苯双酯滴丸及片剂溶出度测定

目的建立联苯双酯滴丸及片剂溶出度测定方法。方法在蒸馏水、乙醇 (φ =4 0 % )和十二烷基硫酸钠水溶液 (ρ =3g·L-1) 3种溶剂中分别测定了不同生产厂家的联苯双酯制剂的溶出度。结果不同生产厂家的联苯双酯制剂的溶出度存在非常显著的差异。结论为制订联苯双酯滴丸溶出度方法提供依据     

复方天宁滴丸制备工艺效应面优化模型的研究

目的 应用星点设计-效应面法优化复方天宁滴丸制备工艺。方法 以PEG6000和棕榈山梨坦(司盘40)为联合基质,以药物的质量分数及PEG6000质量分数为自变量,以丸重差异、溶散时限以及一定时间的阿魏酸溶出度为因变量,对试验数据进行多元线性模型和二项式模型拟合,得出最佳数学模型,绘制效应图和等高线图,再根据效应图优选最佳条件。结果 二项式模型相关系数优于多元线性模型,复相关系数为0.970,复方天宁滴丸最佳处方为药物质量分数23%,PEG6000质量分数47%,模型的理论预测值与实测值偏差较小,模型具有良好的预测性。结论 星点设计-效应面法建立的模型预测性良好,可用于对复方天宁滴丸制备工艺的优化。     

Solubility and dissolution rate of ibuprofen in ionic and non-ionic micellar systems

Equilibrium solubility, the profile and the rate of ibuprofen dissolution in solutions of sodium dodecyl sulfate, Tween 60 and Brij 35 were studied. It was found that the solubility of ibuprofen was enhanced by the formed micellar system. The size and shape of formed micelles depended on the used particular surfactant. The mechanism of ibuprofen dissolution in micellar system was discussed.     

优选砂仁油滴丸成型工艺

目的优选砂仁油滴丸的成型工艺。方法采用正交设计法,对滴丸制备过程中基质配比、滴管内径、挥发油与基质的比例、冷却温度等因素进行考察。通过测定滴丸重量差异,溶散时限以及对滴丸进行外观评价,气相色谱法测定砂仁油滴丸中主要有效成分乙酸龙脑酯的含量,综合确定其最佳成型工艺。结果最佳成型工艺条件为：选择PEG6000/PEG4000（1∶1）为基质,滴管内径为2.0mm,挥发油与基质配比为（1∶2）,冷却温度为0～5℃（冰水浴中）。结论此工艺制备的砂仁油滴丸,每丸中乙酸龙脑酯含量高、滴丸重量差异、溶散时限以及外观评价各指标均达到或优于中国药典2005年版一部要求。